Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Volitionrx (VNRX) EBIAT (2019 - 2025)

Volitionrx filings provide 9 years of EBIAT readings, the most recent being -$6.4 million for Q4 2025.

  • On a quarterly basis, EBIAT fell 9.56% to -$6.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$23.6 million, a 13.21% increase, with the full-year FY2025 number at -$23.5 million, up 13.77% from a year prior.
  • EBIAT hit -$6.4 million in Q4 2025 for Volitionrx, down from -$5.4 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$5.4 million in Q3 2025 to a low of -$9.6 million in Q2 2023.
  • Median EBIAT over the past 5 years was -$7.3 million (2021), compared with a mean of -$7.2 million.
  • Biggest five-year swings in EBIAT: crashed 65.94% in 2021 and later soared 35.36% in 2025.
  • Volitionrx's EBIAT stood at -$8.1 million in 2021, then increased by 9.52% to -$7.3 million in 2022, then fell by 19.95% to -$8.8 million in 2023, then soared by 33.44% to -$5.9 million in 2024, then dropped by 9.56% to -$6.4 million in 2025.
  • The last three reported values for EBIAT were -$6.4 million (Q4 2025), -$5.4 million (Q3 2025), and -$6.3 million (Q2 2025) per Business Quant data.